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Cannabis matters? Treatment responses to increasing cannabis 
presentations in addiction services in England. 
 
Abstract 
Aims To conduct a pilot project exploring how treatment providers understood the increasing 
demand of people presenting to services with cannabis related problems and how they 
responded to the demand for this type of treatment in the absence of an up to date evidence-
base. 
Methods A knowledge exchange event involving treatment providers (n=30) from one region 
in the United Kingdom supplemented by qualitative interviews (n=8) and focus groups with 
drug treatment staff (n=5). A thematic analysis of this material was then conducted. 
Findings Five distinct themes emerged.  First, numerous routes were identified into services 
for problematic cannabis users. Second, access to treatment for some groups is an issue. 
Third, the type of treatment offered varies considerably within and across services. Fourth, 
cannabis use was viewed as benign by many staff and clients with noticeable variations of 
risk. Finally, there is an acknowledgment that the there is an evolving connoisseurship 
associated with contemporary cannabis use whereby the client has increasing expertise in 
relation to contemporary cannabis consumption that has yet to fully filter through to the 
practice of treatment providers. 
Conclusions There appears to be a gap between treatment demand and evidence based 
treatment for cannabis related problems, so that while the trend in treatment demand 
continues to rise the translation of the evidence base into practise for effective treatment 
strategies has not kept pace with this demand. 
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Cannabis matters? Treatment responses to increasing cannabis 
presentations in addiction services in England. 
Introduction 
 
Although cannabis use has recently declined in the United Kingdom (Home Office 2014), 
treatment presentations have risen quite dramatically from 2005 through to 2014 (Public 
Health England 2014, see Figure 1). Moreover it is likely that presentations to treatment 
services represent a fraction of those people who are actually in need of treatment 
(Degenhardt, et al., 2003 Hamilton et al. 2014a). Estimates suggest that as few as 1 in 10 
dependent cannabis users seek treatment in any given year (Gates et al. 2012), pointing to a 
significant proportion of problematic cannabis users who do not present to treatment services.   
Figure 1 here 
 
 
Significant issues stem from this emerging cannabis treatment-seeking population, in terms of 
changing pathways to treatment, changes in treatment options and changes to the drug 
treatment population. With regard to the latter, the UK Government recently acknowledged in 
the most recent drug strategy that: 
…groups of people who would not fit the stereotype of a dependent drug user 
are presenting for treatment in increasing numbers. These individuals are often 
younger and are more likely to be working and in stable housing. We need to 
ensure that provision for these individuals is tailored and responsive (HM 
Government, 2010:6) 
There has been growing interest in the demographic changes in drug use, and the potential 
impact this will have on successful treatment outcomes (Badrakalimuthu et al 2010, Gowing 
et al 2015). The Royal College of Psychiatrists (2011) recently examined this issue making a 
number of recommendations including the need for the ‘examination of trends in the extent, 
nature and predictors of substance use problems in older people’. Similarly Drugscope (2014) 
have reported on the increasing visibility of older drug users presenting to services for 
cannabis related problems. This demographic change in people using cannabis and in those 
seeking treatment observed in the UK has also been observed in the USA where Burns et al 
(2013) found a particularly sharp rise in consumption of cannabis by those aged fifty and 
over. 
Another important contextual factor in the United Kingdom is the change in cannabis type 
over recent years.  Using seizures as a proxy for street availability, data suggest decreasing 
availability of cannabis resin with a corresponding increase in high potency herbal cannabis, 
often referred to as ‘skunk’ (Cascini et al 2012; Di Forti et al, 2015). There has also been the 
appearance of synthetic cannabinoids sold as ‘legal highs’, increasing numbers of which have 
been controlled under the Misuse of Drugs Act (1971). It is not known what effect, if any, 
these factors have had on the increasing numbers of people presenting to treatment services. 
There is currently little definitive information on ways of refining and improving the efficacy 
of cannabis treatment. Studies in Australia of cannabis treatment-seeking clinics show that 
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these are a more attractive environment for those new to drug treatment and potentially 
retains drug users in treatment until treatment is completed, although this could be because 
cannabis only treatment in this context tends to be shorter than non-dedicated treatment 
provision (Copeland and Allsop, 2014). The use of cannabis withdrawal medication is 
restricted in the UK, the only licenced treatment being for the primary treatment of Multiple 
Sclerosis. Therefore, a prescriber who prescribes Sativex for cannabis withdrawal treatment 
would be doing so 'off licence'.  
Relatively little research has been carried out on the topic of cannabis treatment, primarily 
because of what was considered to be the absence of a dependence mechanism, despite the 
fact that research has demonstrated that cannabis users readily respond to information 
identifying treatment as an option (Copeland, 2001). The last Cochrane review on the subject 
of cannabis treatment highlights numerous treatment options (Denis et al 2006). As of June 
2013, the review was withdrawn from publication by the Cochrane Collaboration on the 
grounds that it is ‘substantially out of date’ (Cochrane 2013). It was noted at the time, 
however, that few of the interventions included in the review are well placed to deliver long-
term abstinence. This is true of both face-to-face and remotely delivered interventions such as 
Computer and Internet based interventions (see Tait, et al. 2013). Some interventions are, 
however, successful in ameliorating the impacts of withdrawal or reducing the social impacts 
of cannabis use. Work published subsequently reveals a similar pattern (Danovitch and 
Gorelick, 2012; Copeland and Swift, 2009; Vandrey and Haney, 2009; Elkashef et al., (2008) 
Budney, et al., 2007; Nordstrom and Levin, 2007).  
Existing NICE guidance on cannabis treatment recommends psychosocial interventions 
although it states that CBT and psychodynamic therapy should not be offered as a matter of 
routine (NICE, 2007). Recent systematic reviews have been undertaken. Marshall et al.’s 
review (2014) of evaluations of pharmacotherapies for cannabis dependence found 
pharmacotherapies to be largely ineffective, although again the evidence base was limited. 
Davis et al.’s (2014) report on a meta-analysis of ten RCTs of behavioural interventions (BT) 
for treatment-seeking cannabis users examined a range of options. All interventions included 
Cognitive Behavioural Therapy (CBT) plus contingency management, relapse prevention, 
motivational interviewing or a combination of these. BT was shown to significantly more 
effective in reducing severity and frequency of use than control conditions although, while 
BT outperformed waiting list controls, it did not outperform active control conditions (Davis 
et al., 2014, p.13). Qualified evidence exists, therefore, that combined CBT and behavioural 
therapies may be effective in reducing the severity and frequency of cannabis use. A recent 
review of by the European Monitoring Centre on Drugs and Drug Addiction concluded that 
there was no definitive evidence ‘for the superiority of any specific treatment to others. 
Treatment context and the individual’s choice in entering treatment are more important 
determinants of outcome than treatment modality’ (EMCDDA, 2015, p 61). 
There is, then, something of a knowledge vacuum. A patchwork of evidence exists on 
cannabis treatment, but the last systematic review of the topic was last completed nine years 
ago (Denis et al 2006) precisely at a point when the availability of cannabis type was in flux. 
The situation is compounded by the way that funds are allocated for drug treatment. 
Organisations have to negotiate challenging funding regimes and are often pitted in 
competition with one another to secure finances to deliver needed services. In such an 
environment, opportunities for knowledge exchange become limited. As it stands, there is a 
necessity for learning across the drug treatment sector as to effective interventions for people 
who present with primary problems associated with cannabis. Overall it is uncertain what 
types of interventions are being offered to this new treatment population or how treatment 
providers formulate evidence based services given the lack of available research in this area. 
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Ultimately, little is known about what works, for whom and in what circumstances (Pawson 
and Tilley, 1997) in relation to cannabis treatment. 
Methodology 
The research team carried out a pilot study into the changing patterns of cannabis treatment. 
Initially, this involved scoping the data for emerging trends in cannabis treatment (Hamilton, 
et al., 2014a), which formed the context to an information workshop and knowledge 
exchange event in April 2013. Participants included service user representatives, consultant 
psychiatrists, drugs workers from the statutory and third sector from adult and young people 
providers, mental health workers, from one region of the United Kingdom (n=30). 
Alongside the workshop, follow up semi-structured interviews (n=8) and a focus group with 
5 participants were undertaken drawn with representatives purposively drawn from the above 
sample. The focus group participants consisted of 2 male and 3 female drug workers in the 
statutory and third sector. The main criteria for selection was to engage the views of 
respondents who had been involved in delivering cannabis treatment interventions in the 
twelve months prior to the research commencing. All worked with adult cannabis users in the 
past, although one respondent was currently delivering interventions with younger users.  
We carried out a thematic analysis of the interview and focus group data. The aim was to try 
and ascertain:  
a) In what way treatment providers were meeting the increasing demand of 
people presenting to  services with cannabis related problems and;  
b) How they responded to the demand for this type of treatment. 
The research was given approval by the University of Leeds ethics committee. For reasons of 
confidentiality and anonymity, respondents have been assigned a pseudonym and their place 
of work disguised. 
Findings 
Five distinct themes emerged.  First, numerous routes were identified into services for 
problematic cannabis users. Second, the type of treatment offered varies considerably within 
and across services. Third, access to treatment for some groups is an issue. Fourth, cannabis 
use was viewed as benign by many staff and clients with noticeable variations of risk across. 
Finally there is an acknowledgment that the client has increasing expertise in relation to 
contemporary cannabis consumption that has yet to fully filter through to the practice of 
treatment providers. 
Theme 1: Pathways into Treatment (Routes and Motivations) 
It was apparent from our research that there was a diversity of formal routes into treatment, 
by which we mean the referral process and whether that was initiated by the users themselves 
or via a third party such as their GP, Mental Health Worker, Education System or Criminal 
Justice System. The disparate referral routes are matched by service providers’ interpretation 
on the underlying reasons for why this was necessary. These consistently included: anger, 
anti-social behaviour, family arguments, sexual health issues and stress-related (mental-
health) reasons. In addition, public information campaigns were thought to be a contributing 
factor. Although this was the case, it was also apparent that for several participants this was 
the tip of the iceberg and that problematic cannabis users were not accessing treatment due to 
referrer resistance.  
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There was some variety over the routes through which service users were entering treatment 
and this has a knock-on effect for the service provided. Interview respondent 1, a drugs 
worker for a national service provider highlights some of the complexities over routes into 
cannabis treatment: 
I am seeing a young girl tomorrow who has come through from the mental 
health team.  I got a call from the mental health team: a single mum who has 
tried to – she tried to take her own life last week, cannot stop smoking 
cannabis.  Because of the nature of it, me and a female colleague are going to 
do a home visit because there is a child involved, tomorrow, and do an 
assessment and see how we can help.  We have got another referral…– for a 
young man that has come from a doctor.  So it is always changing.  So when 
you close someone down, you have another one come along, you know. 
(IR4) This respondent confirmed that referrals were instigated through contact with the 
criminal justice system, but were not triggered by drug testing, rather conversations with the 
arrest referral team: 
..if somebody was flagged up as having a cannabis issue, then they would be 
signposted to services. 
It is worth noting that the number of cannabis possession offences recorded by the police 
nearly doubled between 2004/5 and 2011/12, and that cannabis possession accounts for 70% 
of police recorded drug offences (Shiner 2015). With this level of police interest and activity 
it is a possible contributing factor for the increase in presentations to treatment services for 
cannabis. In short the net-widening of the police is matched by treatment services. 
A recurring issue that was thought to trigger self-referral or one instigated by others was 
anger: 
(IR2): 
Anger, that seems to be the biggest one that I’ve come across. 
(IR5): 
Parents will constantly mention that they will get very angry very quickly over 
somewhat-you know, like the smallest request to do something. And that is 
what interests me in terms of – I think that would – for me, is an element of 
cannabis withdrawal that perhaps goes unrecognised. 
(IR6): 
Our service has seen a massive change in trends recently…especially young 
men being very aggressive very angry. 
Anger, aggression and irritability are all recognised as components of cannabis withdrawal 
(Budney et al 2004). Withdrawal could account for the behaviour our respondents report, but 
it could be co-incidental and unrelated, however the frequency with which this issue was 
raised warrants further investigation.  
Theme 2: Access to Treatment Services 
As indicated at the outset, there has been growing concern about the demographic changes in 
drug use, and the potential impact this will have on treatment. Where cannabis is the primary 
issue, these issues seem to be magnified. 
One of our respondents notably reframed the emphasis with regard to accessing treatment: 
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I do not like the phrase hard to reach when it comes to young people and 
substance users. I don’t think that’s true. I think services are hard to access, 
not people being hard to reach. So we have to become flexible in the ways in 
which we work. 
More specific examples of barriers to treatment were expressed by one worker who 
highlighted that although child protection issues have become associated with female opiate 
users there was concern that these were now affecting female cannabis users (IR6): 
There’s a lot of stigma about female adult service users coming into treatment 
where there’s childcare. A lot of stigma about that, a lot of fear, especially 
about how we’re supposed to assess people in this day and age as well. ....I 
think there are more females coming through, but I don’t think we get 
anywhere near the number or the amount… with the amount that are using. 
Gender differences in access to treatment have been observed for some time however little 
attention has been given to the gender imbalance in relation to cannabis treatment (Hamilton 
et al 2015). Females may perceive treatment as male orientated and dominated (Montanari et 
al 2011). Another particular area of interest concerned use amongst BME groups. In one of 
the focus groups, a drug worker/service manager referred to a group of young BME men as 
being heavy end users who were not seeking treatment. It transpired too that there had been 
an emergence of young female Asian users in the same area which raised cultural issues 
about service provision and treatment. Others also suggested that some ethnic minority 
cannabis users do not access treatment services. Interview respondent 7 a senior manager in a 
regional service comments suggested that this is a general problem with health services: 
I think there’s a hidden population that don’t access services.  Whether it’s 
drug treatment services, whether it’s alcohol services, or like primary care or 
health generally, I think that is a problem, a bit of an iceberg and I can’t tell 
you if any – at all, what type of support they are having because it is taboo to 
talk about these things within certain cultures…I think it’s really hard because 
young people wouldn’t make the referral themselves into the service. I think 
we miss a lot of them and I think we are missing a hell of a lot of them, 
especially in children’s home and stuff (IR7). 
Theme 3: Variations of Treatment Practice 
In the UK context, particularly from the late 1990s onwards the treatment context shifted 
(Seddon, 2006). This was most noticeable with the roll-out of quasi-compulsory treatment for 
certain drug and alcohol users in the form of Drug Rehabilitation Requirements and Alcohol 
Treatment Requirements. In essence, there has emerged what we refer to as a clear ‘treatment 
narrative’, which foregrounds substitute treatment. 
The sector faces challenges in developing a coherent programme of treatment for cannabis 
users in the absence of an established substitution prescribing programme as with opioid 
treatment. Interview respondent 8, a support worker for a recovery community in the region 
illustrates the point: 
But with cannabis being a new thing, it’s obviously presenting new challenges 
and how to deal with it…There’s no substitute medication that people can go 
on…    
Here we see some reflection on the lack of treatment narrative for cannabis. It is indicative of 
the lack of available knowledge at the disposal of treatment providers in the region. However 
there was evidence of a range of attempted treatment options provided in the region. 
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According to another respondent his service ‘prescribed treatment like anti-anxiety 
medication’ (IR7) but others used ‘a more proactive assertive outreach as well as reactive 
crisis intervention work ’ (IR1).  
 
if someone drops out of treatment for whatever reason, a referral comes 
through to me and I will… go try and find them...make sure they are all right, 
find out what is going on, why they may have dropped out of treatment, and 
try and facilitate them back in if they want that.  But the prime, main reason is 
to make sure they are okay.   
The focus group revealed other techniques, mainly revolving around ‘psychosocial 
interventions’: 
We tend to use lots of drug diaries, lots of targets and ‘what kind of two or 
three things are you going to try to change or alter this week’ sort of thing  
There was a sense also that the treatment offered was contingent on the needs of the 
particular client as for interview respondent 6 and her work with younger groups the diary 
approach was seen to be less useful: 
because we’re not looking at someone that’s doing it every single day or four 
or five times a week…we can’t measure it because they’re doing it as a peer 
group… We tend to work with young people for three to six months doing one-
to-one psychosocial interventions.  So, the CBT, the motivational interview in 
terms of looking at motivation to change (IR6). 
IR7 noted that ‘contingency management’ was at the fore of their service delivery: 
We’d heard about this before… in addition to psychological interventions, like 
psychosocial interventions, combining contingency management which 
provides money or other incentives for attending appointments, or for 
producing drug negative urinalysis results.  It [is supposed] to improve 
abstinence outcomes during and after treatment.  However, it is unknown 
whether advantages of contingency management with motivation enhancement 
therapy or CBT outweigh the extra costs associated with contingency 
management.  So it’s another option, but it’s just whether or not it’s as 
effective and there’s still a lot more research.  But yeah that was an 
interesting one.  So paying clients for attending appointments, paying clients 
to provide negative samples 
There is some sense that service providers in the region are using therapies widely discussed 
in the literature, although their application to problematic cannabis users has yet to be 
evidenced. Others, meanwhile, seem to be employing service specific interventions.  
Theme 4: Benign nature of cannabis 
There has also been a long-standing tendency for policy-makers and practitioners to ignore or 
downplay problems with cannabis: a situation that Michael Dennis and colleagues have 
referred to as ‘benign neglect’ (Dennis et al., 2002). This is reinforced by the scant attention 
paid to problematic cannabis use in the 2010 drug strategy and subsequent annual reviews 
(HM Government, 2015). There was a sense that the benign neglect of cannabis had filtered 
down to the service level. Indeed, a common line of argument was the perception that 
cannabis was generally viewed by both the general population and by other key workers 
(including by other treatment workers) as being relatively harmless vis-à-vis heroin, 
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mirroring previous research in this area (e.g. Pinikahana et al, 2002). For example, prevailing 
attitudes of the benign nature of cannabis are clearly expressed by IR1:  
I know there are people... who …would be absolutely delighted if some of their 
clients stop using heroin, stop using crack cocaine, and the only drug they 
were using after that was cannabis.  I think some would deem that as a 
success in that client’s recovery programme.  
This view of cannabis has to be understood within the historic emphasis of targeting and 
treating predominantly people who use opiates and the health and social problems associated 
with this type of treatment presentation.  
If someone tested positive to cannabis it was dismissed, we were more 
intrigued about the class A drugs. 
(IR4): 
..if you’re not injecting heroin or whatever or you’re only using weed, and 
there is this kind of stereotype that weed, cannabis, is a much lesser drug, you 
know, “What do you mean you’ve got an issue with it?” sort of, kind of thing. 
(IR5): 
..I think, also, is this king of mythology that cannabis is harmless. 
(IR6)  
there was a little bit of judgement – yes I think the service as a whole was 
quite judgemental in terms of well, working with crack and heroin users, 
they’ve got such chaotic lives the cannabis users not so much. 
Most respondents had worked in drug treatment services for some time and as is apparent 
from the quotes recognised the shift in attitude that was required in relation to cannabis. 
Elsewhere a subtheme to emerge from our research was a definite sense of an 
intergenerational chasm in understandings of the perceived harms of cannabis. In this case the 
context is that of the family as it was widely suggested that cannabis initiation and 
subsequent use takes place in the family setting and that this in turn may be downplaying the 
seriousness of cannabis use for certain individuals. Interview respondent 6 explains: 
there’s a couple of lads that I’m working with now, Dad smokes and you know 
it’s okay, Dad’s always smoked, it’s never been an issue.  Therefore if they’ve 
got that perception then they tend to believe that and then when you come in 
and start talking about some of the risks, they don’t believe what you’re trying 
to say.  So there’s a lot of that going on in families. 
The focus group covered similar terrain. In response to a question about different perceptions 
of cannabis use, our respondents noted: 
FG1  you get some that are smoking a lot more and that's not perceived as a 
problem because my dad smokes weed, I smoke skunk so we're all - that's all 
right.   
FG2 I think in some families… it's perceived as the lesser of some of the 
evils.   
FG4 I think where you see the difference is the older generations are 
smoking cannabis not skunk.  So it won't cause them quite the level of 
problems mentally and criminally, all that kind of stuff.  However the children 
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are now reverting to strong cannabis and it becomes problematic, the whole 
lifestyle and behaviours are different to the parent. 
The benign neglect of cannabis in policy circles seemed to translate into making cannabis a 
low priority for services over a number of years. This was reinforced by a sense that there 
were significant intergenerational differences in appreciations over the risks associated with 
cannabis use.  As the levels of cannabis users seeking or entering treatment for cannabis 
problems has recently risen, there was a sense that the services and the personnel lack the 
knowledge and skills to accommodate this new clientele, typified by the variations in 
treatment practice discussed earlier. This is compounded, furthermore, by a systemic 
challenge for the sector whereby there is a lack of emphasis on the treatment of cannabis 
users and where knowledge of the drug and its effects lags behind that of the users. 
Theme 5: Changing Nature of ‘Expertise’ 
A significant recent development in the emerging drug markets has been the rise of twin 
markets in herbal and synthetic cannabis. As regards the former, there is a sense that ‘home 
grown’ cannabis relying on often sophisticated production techniques has entered the market 
place at significant levels (Potter et al 2014). Alongside this, synthetic cannabinoids, often 
produced and marketed as replacements for the ‘real thing’ (Winstock et al 2015) are 
similarly more widely available. For example, products such as ‘Spice’ have emerged which 
are supposed to recreate the effects of cannabis. In our research the former seemed to 
represent more of an issue than the latter as synthetic cannabinoid use was not perceived by 
our respondents to be a significant issue across this particular region: 
I’ve not seen it much.  I’ve really not seen it.  I’ve seen – a couple of young 
people have said to me they’re not interested in it because it’s too different [in 
terms of ]effects, that they’ve got no interest in it whatsoever.  … it doesn’t 
seem to have hit off I don’t think massively[FG3]. 
Interview respondent 3 a drugs worker from a large provider in one of the major cities 
stated:   
…one thing I haven't actually seen so much here is the ascension of 
cannabinoids as well.  Because in [town in North-West] that was a really big 
thing.  Quite an emerging big thing really.  And one of the things that you'd 
sort of notice with that is that the synthetic cannabinoid did seem to give much 
more of a negative experience on the whole than cannabis would give.  
However, the increasingly sophistication of cannabis production techniques had led to 
increasing choice of cannabis products. In turn this has created a feeling that there is a sense 
of connoisseurship around the drug, creating a knowledge mismatch whereby the nature of 
cannabis is changing but the learning and skill set of service providers has remained fixed: 
I mean I think certainly if you went back - the further you go back, certainly if 
you went as far back as the eighties or whatever when people were buying 
weed they'd just be buying what they could get sort of thing.  Whereas, I've 
known… people will select particular kinds and they will - they won't smoke 
this and they will smoke that, but they prefer this. (IR2).   
Some respondents vocalised their lack of knowledge in relation to cannabis, its effects and 
how to respond to those seeking help. 
(IR1): 
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..workers aren’t familiar with cannabis users and how to work with cannabis 
users, they’re not confident in working with how to do it – “Oh, I don’t want 
to, I don’t know how to work with someone that’s used cannabis. I don’t know 
what to do.” And these are qualified nurses that have been qualified for years 
and working in treatment services for years. 
This contrast between the workers lack of knowledge with regard to cannabis and the 
expertise and knowledge of the client provides an interesting contrast. Furthermore, it 
suggests that growth in manufacturing of cannabis creates greater choice with specifications 
being refined around types and strains which sees the user situated as ‘expert’. The service 
provider may find themselves in the position, then, of ‘novice’, not privy to this developing 
culture around usage with technological advances production underpins. Further to this, as 
technology facilitates and speeds supply it advances production and potency to the extent that 
progress may outpace the knowledge service providers have of the substances their clients are 
using. 
 
Discussion 
Overall, although more contact was being made with treatment services for cannabis 
problems, there was little consensus among service providers as to what was the most 
effective course of action. This is perhaps unsurprising given the lack of consensus from the 
literature in this regard. In effect, providers felt that for cannabis users there was not a 
treatment narrative in the same way that one had emerged for opiate users based around a 
substitution prescribing model, reflecting the relative absence of a pharmacotherapy solution 
specifically for cannabis. The main themes and messages that emerged were that there was an 
eclectic mix of interventions offered by providers which again is not surprising given the 
varied presenting needs of individuals. That said, it was also the case that services are hard to 
access for some groups and as a consequence cannabis treatment presentations may increase 
over time as services respond accordingly. Despite increasing presentations to treatment, 
some workers continue to view cannabis as benign and intergenerational use is a possible 
explanation for why this is so. Finally, an interesting juxtaposition has developed where 
cannabis users have become ‘expert’ while treatment providers are ‘novice’ in terms of their 
knowledge and ability to recognise and offer bespoke treatment to the cannabis connoisseur. 
Based on our study, we would offer the following suggestions for future research into the 
emerging cannabis treatment population.  
1. Our research suggested that more people were using strains of higher potency 
cannabis and less synthetic variants. Although this is probably localised, 
national studies should investigate the changing markets of cannabis and how 
consumers and users negotiate this 
2. As the general problem drug user population has been in decline, it is possible 
that drug services are spreading their net wider and have been more willing to 
engage and accept people who use cannabis in a problematic way. Indeed, the 
recovery agenda could directly or unintentionally be encouraging workers and 
services to include and accept cannabis use as a contemporary and primary 
problem. Future research should consider in more detail the pathways into 
treatment for those experiencing problems with cannabis. 
3. Although cannabis related problems span all ages and backgrounds, there is 
still a lack of knowledge about the profile and needs of users who experience 
such problems (Temple et al 2011). It is also the case that organisations are 
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grappling with the demands of new and often reduced funding structures 
including a hugely competitive tendering process for the delivery of services 
where more needs to be delivered for less. As it stands, there is a necessity for 
learning across the drug treatment sector as to effective interventions for 
people who present with primary problems associated with cannabis.   
 
Conclusion 
There appears to be a gulf between the demand and supply of evidence based treatment for 
cannabis related problems. While the trend in treatment demand continues to rise the 
translation of the evidence base into practise for effective treatment strategies has not kept 
pace with this demand. We have put forward five, somewhat tentative reasons for this. First, 
the routes into services for problematic cannabis users are unclear which has a knock-on 
effect for the kinds of provision offered. Second, access to treatment for problematic cannabis 
use reflects broader barriers experienced by other treatment seekers. The services are in effect 
hard to access for those from BME backgrounds and females. Third, the type of treatment 
offered varies considerably within and across services, with little understanding therefore of 
what works, for whom, in what circumstances and in what respects (Pawson and Tilley, 
1997). Fourth, cannabis use was viewed as relatively harmless by many staff with noticeable 
variations of risk.  This has been reflected in policy circles over recent years (Dennis, et al., 
2002). Finally, there is an acknowledgment that the client has increasing expertise in relation 
to cannabis consumption stemming from a certain connoisseurship that has emerged in 
relation to contemporary cannabis choice. This knowledge base has yet to be matched by 
those responsible for providing treatment. Ultimately, there is a disjunction between 
evidence, policy and practice in the provision of cannabis treatment at a point in time when 
cannabis matters. 
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